Michael Riella

Mike Riella helps companies structure and execute strategic M&A and capital markets transactions, and navigate the evolving corporate governance and securities disclosure landscape. Mike’s practice focuses on public and private mergers and acquisitions, acquisitions and divestitures of pharmaceutical and biologic products, securities offerings and corporate governance. His transactional experience extends throughout the United States, Europe and Asia.

Mike represents clients principally in the life sciences, health care, gaming, media and technology industries. His experience includes advising Merck on its multibillion acquisitions of Pandion Therapeutics, ArQule, and Antelliq Group, and on its acquisition of Themis Bioscience, a SARS-CoV-2 candidate developer. Other representative clients include Aristocrat, AstraZeneca, Boehringer Ingelheim, Eisai, Elanco, Emergent BioSolutions, Insmed and REGENXBIO.

His pro bono activities include advising nonprofit organizations in the DC metropolitan area regarding governance, strategic planning, commercial and general corporate matters.